JP2017519736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519736A5 JP2017519736A5 JP2016569664A JP2016569664A JP2017519736A5 JP 2017519736 A5 JP2017519736 A5 JP 2017519736A5 JP 2016569664 A JP2016569664 A JP 2016569664A JP 2016569664 A JP2016569664 A JP 2016569664A JP 2017519736 A5 JP2017519736 A5 JP 2017519736A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- class iii
- combination
- kit
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 6
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 claims 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 229950008692 foretinib Drugs 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 108010002164 tyrosine receptor Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409488.2A GB201409488D0 (en) | 2014-05-28 | 2014-05-28 | Pharmaceutical composition |
| GB1409488.2 | 2014-05-28 | ||
| PCT/EP2015/061569 WO2015181154A1 (en) | 2014-05-28 | 2015-05-26 | Pharmaceutical combination comprising a class iii receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule edo-s101 together with its use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519736A JP2017519736A (ja) | 2017-07-20 |
| JP2017519736A5 true JP2017519736A5 (enExample) | 2018-07-05 |
Family
ID=51177590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569664A Withdrawn JP2017519736A (ja) | 2014-05-28 | 2015-05-26 | クラスｉｉｉ受容体チロシンキナーゼインヒビター及びアルキル化ヒストンデアセチラーゼインヒビター融合分子ｅｄｏ−ｓ１０１を含む医薬組合せ、並びに癌の処置におけるその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9993482B2 (enExample) |
| EP (1) | EP3148533A1 (enExample) |
| JP (1) | JP2017519736A (enExample) |
| KR (1) | KR20170005125A (enExample) |
| CN (1) | CN106470701A (enExample) |
| AU (1) | AU2015266050A1 (enExample) |
| CA (1) | CA2950625A1 (enExample) |
| EA (1) | EA201692470A1 (enExample) |
| GB (1) | GB201409488D0 (enExample) |
| IL (1) | IL249228A0 (enExample) |
| MX (1) | MX2016015435A (enExample) |
| PH (1) | PH12016502353A1 (enExample) |
| SG (1) | SG11201609363RA (enExample) |
| TW (1) | TW201613578A (enExample) |
| WO (1) | WO2015181154A1 (enExample) |
| ZA (1) | ZA201607425B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2016426574B2 (en) * | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| EP4213844A4 (en) * | 2020-09-17 | 2024-11-20 | Mirati Therapeutics, Inc. | POLYTHERAPIES |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5882941A (en) | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| WO1998056422A1 (en) | 1997-06-13 | 1998-12-17 | The University Of Kansas | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US20020076409A1 (en) | 2000-07-12 | 2002-06-20 | March Carl J. | Method for treating cancer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| WO2002026696A1 (en) | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| CN1764648A (zh) | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
| WO2004076386A2 (en) | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
| EP1745022B1 (en) | 2004-04-05 | 2014-08-13 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN102579417B (zh) | 2005-05-13 | 2014-11-26 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| JP2009532503A (ja) * | 2006-04-05 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 癌を処置するための治療剤の組合せ |
| UA95310C2 (ru) | 2006-10-20 | 2011-07-25 | Айкос Корпорейшен | Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака |
| GB0621160D0 (en) | 2006-10-24 | 2006-12-06 | Imp College Innovations Ltd | Compounds and uses thereof |
| DE602007009717D1 (de) | 2006-11-20 | 2010-11-18 | Cephalon Inc | Verfahren zur strahlensensibilisierung von tumoren mit einem strahlensensibilisierungsmittel |
| CN101084876A (zh) | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009067453A1 (en) | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| US8987468B2 (en) | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| WO2010036702A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| EP2346836B1 (en) | 2008-10-08 | 2018-03-07 | Cephalon, Inc. | Processes for the preparation of bendamustine |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| DK2389375T3 (en) | 2009-01-23 | 2015-08-24 | Euro Celtique Sa | Hydroxamsyrederivater |
| CA2753641C (en) | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| KR20110140126A (ko) * | 2009-04-16 | 2011-12-30 | 머크 샤프 앤드 돔 코포레이션 | 항-ｅｇｆｒ 작용제(들) 및 ｉｇｆ-1ｒ 특이적 억제제를 사용하는 조합 요법 |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| CN101928234B (zh) | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法 |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| NZ621221A (en) | 2011-09-13 | 2016-07-29 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| CN102993102B (zh) | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
| CN103826630B (zh) * | 2011-09-18 | 2016-12-07 | 杭州民生药物研究院有限公司 | 药物组合物 |
| EP2760860B8 (en) | 2011-09-28 | 2017-03-08 | Euro-Celtique S.A. | Nitrogen mustard derivatives |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
-
2014
- 2014-05-28 GB GBGB1409488.2A patent/GB201409488D0/en not_active Ceased
-
2015
- 2015-05-26 US US15/314,167 patent/US9993482B2/en active Active
- 2015-05-26 KR KR1020167035842A patent/KR20170005125A/ko not_active Withdrawn
- 2015-05-26 AU AU2015266050A patent/AU2015266050A1/en not_active Abandoned
- 2015-05-26 SG SG11201609363RA patent/SG11201609363RA/en unknown
- 2015-05-26 MX MX2016015435A patent/MX2016015435A/es unknown
- 2015-05-26 WO PCT/EP2015/061569 patent/WO2015181154A1/en not_active Ceased
- 2015-05-26 CA CA2950625A patent/CA2950625A1/en not_active Abandoned
- 2015-05-26 EP EP15723979.9A patent/EP3148533A1/en not_active Withdrawn
- 2015-05-26 TW TW104116782A patent/TW201613578A/zh unknown
- 2015-05-26 JP JP2016569664A patent/JP2017519736A/ja not_active Withdrawn
- 2015-05-26 CN CN201580028027.4A patent/CN106470701A/zh active Pending
- 2015-05-26 EA EA201692470A patent/EA201692470A1/ru unknown
-
2016
- 2016-10-27 ZA ZA2016/07425A patent/ZA201607425B/en unknown
- 2016-11-25 PH PH12016502353A patent/PH12016502353A1/en unknown
- 2016-11-27 IL IL249228A patent/IL249228A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518291A5 (enExample) | ||
| JP2021059579A5 (enExample) | ||
| JP2017518292A5 (enExample) | ||
| WO2025067459A2 (en) | Therapies for the treatment of cancer | |
| JP6382516B2 (ja) | 抗腫瘍アルカロイドを用いる、組み合わせの治療法 | |
| JP2021046446A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| ES2941894T3 (es) | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama | |
| JP2019517549A5 (enExample) | ||
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2014509659A5 (enExample) | ||
| JP2017519736A (ja) | クラスｉｉｉ受容体チロシンキナーゼインヒビター及びアルキル化ヒストンデアセチラーゼインヒビター融合分子ｅｄｏ−ｓ１０１を含む医薬組合せ、並びに癌の処置におけるその使用 | |
| JP2014512355A5 (enExample) | ||
| CN103889409A (zh) | N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案 | |
| CN113597309B (zh) | 抗肿瘤组合物 | |
| JP5683462B2 (ja) | オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ | |
| TW201716085A (zh) | 癌症之組合療法 | |
| JP5945863B2 (ja) | 腎細胞がん治療剤 | |
| US20190133998A1 (en) | Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents | |
| CN114430681A (zh) | 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 | |
| JP2025538876A (ja) | がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ | |
| HK40058495B (zh) | 抗肿瘤组合物 | |
| HK40058495A (en) | Antitumor composition | |
| US20100022553A1 (en) | Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib | |
| CA2638270A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and imatinib |